Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

John Mascarenhas, Tsewang Tashi, Firas El Chaer, Victor Priego, Oleh Zagrijtschuk, Albert Qin, Jewell Jessup, Craig Zimmerman, Ray Urbanski, Lucia Masarova

Blood (2023) 142 (Supplement 1): 6444.

https://doi.org/10.1182/blood-2023-189912

Published: 2023

Journal Articles

A Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

John Mascarenhas, Oleh Zagrijtschuk, Craig Zimmerman, Albert Qin, Raymond W Urbanski

Blood (2022) 140 (Supplement 1): 6748–6749.

https://doi.org/10.1182/blood-2022-162693

Published: 2022

Journal Articles

Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia

Ruben A. Mesa, Norio Komatsu, Harinder Gill, Jie Jin, Sung-Eun Lee, Hsin-An Hou, Toshiaki Sato, Albert Qin, Raymond Urbanski, Weichung Shih, Oleh Zagrijtschuk, Craig Zimmerman, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 1491.

https://doi.org/10.1182/blood-2021-147417

Published: 2021

Journal Articles

Ropeginterferon Demonstrates Safety and Efficacy in Myelofibrosis: Pilot Study Results

Jeanne M. Palmer, MD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, John Camoriano, MD, Craig Zimmerman, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-138934

Published: 2020

Journal Articles

Clinical Benefit of Ropeginterferon Alfa 2b (P1101) in Patients with Myelofibrosis

Jeanne Palmer, MD, Heidi E. Kosiorek, MS, Craig Zimmerman, PhD, Oleh Zagrijtschuk, MD, John Camoriano, MD, Ruben A. Mesa, MD

Blood (2018) 132 (Supplement 1): 5475.

https://doi.org/10.1182/blood-2018-99-115521

Published: 2018

NARROW

A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

A Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia

Ropeginterferon Demonstrates Safety and Efficacy in Myelofibrosis: Pilot Study Results

Clinical Benefit of Ropeginterferon Alfa 2b (P1101) in Patients with Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

A Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia

Ropeginterferon Demonstrates Safety and Efficacy in Myelofibrosis: Pilot Study Results

Clinical Benefit of Ropeginterferon Alfa 2b (P1101) in Patients with Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only